Navigation Links
Athera Signs Distribution Agreement in Scandinavia

Athera Signs Distribution Agreement in Scandinavia -- STOCKHOLM, August 27, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Contracts, New Products & Services Click to view news release full screen  

Athera Signs Distribution Agreement in Scandinavia


STOCKHOLM, August 27, 2010 /PRNewswire/ -- Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio.

Carina Schmidt, VD i Athera:

"This is an important step in the broader commercialization of CVDefine. Together with Electra-Box we will now be able to expand our contacs with leading clinial scientist in the cardiovascular field and increase the exposure of our trademark. We look forward to be able to work with the experienced Electra-Box team."

Peter Blom, responsible for clinical chemistry in Electra-Box Diagnostica: "We are very excited about the opportunities this agreement present. This will allow us to offer a new CVD biomarker to customers in Scandinavia. Since CVDefine(R) may add important and independent information in cardiovascular risk assessment; we believe there is a lot of interest from scientist in the field to generate further clinical research data".

High levels of IgM antibodies against phosphorylcholine (anti-PC) have been shown to be cardio-protective. Low levels of anti-PC are known to be involved in atherosclerosis development and increased risk for acute cardiovascular events, like stroke and myocardial infarction. Athera is investigating the possibilities to develop new immunological therapies to prevent secondary cardiovascular events and to identify the patients who benefit most from this treatment with CVDefine, and consequently contribute to better care after acute heart disease.

To The Editors

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is part of the Karolinska Development AB (publ) portfolio.

About CVDefine

CVDefine(R) is a diagnostic test measuring IgM anti-bodies against phosphorylcholine (anti-PC). Low levels of anti-PC indicate a risk for future development of cardiovascular disease (CVD). CVDefine(R) is an ELISA kit for early detection of increased cardiovascular risk due to atherosclerosis and vascular inflammation.

About Karolinska Development (publ)

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products.

About Electra-Box Diagnostica AB:

Electra-Box Diagnostica is a distribution company for products to research and clinical laboratories in Sweden, Denmark, Norway, Finland and Baltic countries.

For additional information, please contact: Carina Schmidt, CEO Athera Biotechnologies AB Phone: +4670-552-5115 E-mailt:

SOURCE Athera Biotechnologies AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Athera Receives Allowance of Two Key Patents
2. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
3. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market
6. Microbix Signs $2 Million Partnership Agreement For its Livestock Semen Sexing Technology (LumiSort(TM))
7. Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract
8. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
9. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
10. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
11. Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):